Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis

Published:2019-11 Issue:12 Volume:71 Page:1976-1984
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Schanberg Laura E.¹,Ramanan Athimalaipet V.²,De Benedetti Fabrizio³,Beukelman Timothy⁴,Eakin Guy S.⁵,Del Gaizo Vincent⁶,Ringold Sarah⁷,Vesely Richard⁸,Schrandt Suzanne⁵,Jaki Thomas⁹,Bili Androniki¹⁰,Chung James B.¹¹,De Bono Stephanie¹²,Douglass Wendy¹³,Enejosa Jeffrey V.¹⁴,Kanik Keith S.¹⁵,Knobe Karin¹⁶,Kunder Rebecca¹⁷,Leite‐Schnell Juliana C.¹⁴,Suehiro Ricardo Maisse¹⁸,Wong Robert L.¹⁹,Mieszkalski Kelly L.⁶,Marrow Laura C.⁵,Siebenaler Kristin²⁰,Fraulo Elizabeth¹,Kimura Yukiko²¹^ORCID

Affiliation:

1. Duke University Medical Center Durham North Carolina

2. University Hospitals Bristol NHS Foundation TrustBristol Medical SchoolUniversity of Bristol Bristol UK

3. Ospedale Pediatrico Bambino Gesù Rome Italy

4. University of Alabama at Birmingham

5. Arthritis Foundation Atlanta Georgia

6. Childhood Arthritis and Rheumatology Research Alliance Milwaukee Wisconsin

7. Seattle Children's Hospital Seattle Washington

8. European Medicines Agency London UK

9. Lancaster University Lancaster UK

10. Janssen Immunology R&D Spring House Pennsylvania

11. Amgen Inc. Thousand Oaks California

12. Eli Lilly Basingstoke UK

13. Roche Basel Switzerland

14. AbbVie Inc. North Chicago Illinois

15. Global Product DevelopmentPfizer Inc. New London Connecticut

16. Sobi Stockholm Sweden

17. Gilead Sciences, Inc. Foster City California

18. Pfizer Inc Collegeville Pennsylvania

19. Bristol‐Myers Squibb Princeton New Jersey

20. Duke Clinical Research Institute Durham North Carolina

21. Hackensack University Medical Center Hackensack New Jersey

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.41043

Reference41 articles.

1. Characteristics and Changes of Pediatric Therapeutic Trials under the Best Pharmaceuticals for Children Act

2. Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases

3. Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016

4. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation

5. Systemic juvenile idiopathic arthritis: New insights into pathogenesis and cytokine directed therapies

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sample Size Calculation for an Individual Stepped‐Wedge Randomized Trial;Biometrical Journal;2024-07

2. Towards molecular-pathology informed clinical trials in childhood arthritis to achieve precision medicine in juvenile idiopathic arthritis;Annals of the Rheumatic Diseases;2022-12-05

3. Spectrum of Clinical Research in Juvenile Idiopathic Arthritis: A Cross-Sectional Analysis of Registered Studies in Clinicaltrials.gov and Clinicaltrialsregister.eu;Biomedicines;2021-12-08

4. CARRA;Rheumatic Disease Clinics of North America;2021-11

5. Pharmacosurveillance in Juvenile Idiopathic Arthritis;Rheumatic Disease Clinics of North America;2021-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3